WO2013063186A2 - Monoclonal antibodies and methods of use - Google Patents

Monoclonal antibodies and methods of use Download PDF

Info

Publication number
WO2013063186A2
WO2013063186A2 PCT/US2012/061782 US2012061782W WO2013063186A2 WO 2013063186 A2 WO2013063186 A2 WO 2013063186A2 US 2012061782 W US2012061782 W US 2012061782W WO 2013063186 A2 WO2013063186 A2 WO 2013063186A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
canine
amino acid
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/061782
Other languages
English (en)
French (fr)
Other versions
WO2013063186A3 (en
Inventor
Sarah Rue
Brendan ECKELMAN
Quinn Deveraux
Marc Nasoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Novartis Animal Health US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2853637A priority Critical patent/CA2853637C/en
Priority to EP18165199.3A priority patent/EP3378489A1/en
Priority to US14/354,280 priority patent/US9790280B2/en
Priority to RU2014120804A priority patent/RU2623122C2/ru
Priority to EP12842976.8A priority patent/EP2771694A4/en
Priority to JP2014538974A priority patent/JP6316195B2/ja
Priority to BR112014010008A priority patent/BR112014010008A2/pt
Priority to AU2012328819A priority patent/AU2012328819B2/en
Application filed by Novartis Animal Health US Inc filed Critical Novartis Animal Health US Inc
Priority to EP24217016.5A priority patent/EP4530630A3/en
Publication of WO2013063186A2 publication Critical patent/WO2013063186A2/en
Anticipated expiration legal-status Critical
Publication of WO2013063186A3 publication Critical patent/WO2013063186A3/en
Priority to US15/685,257 priority patent/US11319377B2/en
Priority to US17/703,542 priority patent/US20220251230A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the binding agents that are to be compared are added to / placed in proximity with, the target to which the binding agents are capable of binding or suspected of binding.
  • the experiments are designed so it is possible to quantify binding of the individual binding agents to the target. Competition is found, for example, when addition of at least one "A” antibody results in binding of a "B” antibody to a lesser degree than if the "A” antibody were not present.
  • binding agent "A” competes with binding agent "B” for binding to the target.
  • “B” may also compete with “A.”
  • the "A” and “B” antibodies may or may not have substantially similar Kd's.
  • GAGGTTCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAGGCCAG encoding SEQ ID GGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTTAATAT NO.: 15 (1G1, V H ) TAAAGACGACTATATGCACTGGGTGAAGCAGAGGCCTGAACAG
  • variable region sequences described herein may comprise fragments and / or derivatives thereof), including but not limited to the amino acid sequences shown in Table 1 (and / or fragments and / or derivatives thereof) and / or the nucleotide sequences shown in Table 1 (and / or fragments and / or derivatives thereof) may be used in combination with one or more amino acid sequences and / or nucleotide sequences encoding one or more constant chains (and / or a fragment and / or derivatives thereof) of an antibody molecule.
  • amino acid residues potentially susceptible to post-translational deamidation may be substituted to modify the NG sequence (see, e.g., SEQ ID NOS. 71, 73, 75 and 77).
  • SEQ ID NO.: 3 is shown below, with N33 and G34 (an NG sequence) underlined:
  • N33 (of, e.g., SEQ ID NO.: 9) may be substituted by lysine (K) (N33K substitution).
  • G34 (of, e.g., SEQ ID NO.: 9), may be substituted by lysine (K) (G34K), glutamine (Q) (G34Q), or alanine (A) (G34A).
  • the substitutions may include N33K and any of G34K, G34Q, or G34A. Other substitutions may also be suitable as would be understood by one of ordinary s kill in the art.
  • binding to CD16A of the M120A- and L121A-containing molecule was not reduced as much as for binding of the M120P and LI 21 A molecule, or as much as for binding of the N 183 A molecule.
  • the bound protein may then be separated from the antibody and analyzed as desired. Similar methods for isolating a protein using an antibody are well-known in the art.
  • the binding agents e.g., antibodies
  • the binding agents may also be utilized to detect CD20 protein within a biological sample.
  • the antibodies may be used in assays such as, for example, flow cytometric analysis, ELISA, immunoblotting (e.g., western blot), in situ detection, immunocytochemistry, and / or immunohistochemistry. Methods of carrying out such assays are well-known in the art.
  • binding agents may also be combined with or used in conjunction with (e.g., as part of a treatment regimen) other anti-cancer agents such as, for example, cyclophosphamide (e.g., Cytoxan, Neosar), Adriarnycin (e.g., doxorubicin /
  • the binding agents may also be used treat various autoimmune diseases.
  • Expression profile assays may be used to determine the relative level of expression of CD20.
  • the level of expression may then be correlated with base (e.g., control) levels to determine whether a particular disease is present within the patient, the patient's prognosis, or whether a particular treatment regimen is effective. For example, if the patient is being treated with a particular chemotherapeutic regimen, a decreased level of expression of an chemotherapeutic regimen.
  • Conservative amino acid substitutions may involve a substitution of a native amino acid residue with a non-native residue such that there is little or no effect on the size, polarity, charge, hydrophobicity, or hydrophilicity of the amino acid residue at that position and, in particular, does not result in decreased immunogenicity. Suitable conservative amino acid substitutions are shown in Table 7.
  • compositions may also include carriers, thickeners, diluents, buffers, preservatives, surface active agents, adjuvants, immunostimulants, in addition to the immunogenic polypeptide, or the anti-CD20 antibodies.
  • Canine PBMCs were isolated by red blood cell lysis, labeled with propidium iodide, and stained with 1E4 antibody (1 ⁇ g antibody/ml) and anti-mouse Fab-APC (1/200) from Jackson Immunoresearch # 115-136-146 as the secondary antibody (secondary antibody alone was used as a negative control).
  • the primary FACS gate was on lymphocytes (left panels). Only live lymphocytes (those that did not stain with propidium iodide) were included in the analysis (middle panels).
  • the 1E4 chimeric canine IgGB antibody described above is administered to Beagle male dogs having B cell lymphoma at an appropriate dose (e.g., 10 mg / kg) via intravenous bolus injection. Blood is collected from animals at various days including Day 0 (pre-dose) and, for example, Day 1, Day 2, Day 3, Day 4, Day 7, Day 10, Day 14, Day 28, Day 42, and Day 59.
  • an appropriate dose e.g. 10 mg / kg
  • Blood is collected from animals at various days including Day 0 (pre-dose) and, for example, Day 1, Day 2, Day 3, Day 4, Day 7, Day 10, Day 14, Day 28, Day 42, and Day 59.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2012/061782 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use Ceased WO2013063186A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR112014010008A BR112014010008A2 (pt) 2011-10-26 2012-10-25 anticorpos monoclonais, seus usos e ácidos nucleicos
US14/354,280 US9790280B2 (en) 2011-10-26 2012-10-25 Monoclonal canine CD20 antibodies and methods of use
RU2014120804A RU2623122C2 (ru) 2011-10-26 2012-10-25 Моноклональные антитела и способы их применения
EP12842976.8A EP2771694A4 (en) 2011-10-26 2012-10-25 MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
JP2014538974A JP6316195B2 (ja) 2011-10-26 2012-10-25 モノクローナル抗体および使用の方法
AU2012328819A AU2012328819B2 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use
EP24217016.5A EP4530630A3 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use
CA2853637A CA2853637C (en) 2011-10-26 2012-10-25 Anti-canine cd20 monoclonal antibodies and methods of use
EP18165199.3A EP3378489A1 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use
US15/685,257 US11319377B2 (en) 2011-10-26 2017-08-24 Monoclonal antibodies and methods of use
US17/703,542 US20220251230A1 (en) 2011-10-26 2022-03-24 Monoclonal antibodies and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161551918P 2011-10-26 2011-10-26
US61/551,918 2011-10-26
US201261699300P 2012-09-11 2012-09-11
US61/699,300 2012-09-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/354,280 A-371-Of-International US9790280B2 (en) 2011-10-26 2012-10-25 Monoclonal canine CD20 antibodies and methods of use
US15/685,257 Continuation US11319377B2 (en) 2011-10-26 2017-08-24 Monoclonal antibodies and methods of use

Publications (2)

Publication Number Publication Date
WO2013063186A2 true WO2013063186A2 (en) 2013-05-02
WO2013063186A3 WO2013063186A3 (en) 2014-07-31

Family

ID=48168777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/061782 Ceased WO2013063186A2 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use

Country Status (8)

Country Link
US (3) US9790280B2 (enExample)
EP (3) EP3378489A1 (enExample)
JP (1) JP6316195B2 (enExample)
AU (1) AU2012328819B2 (enExample)
BR (1) BR112014010008A2 (enExample)
CA (1) CA2853637C (enExample)
RU (1) RU2623122C2 (enExample)
WO (1) WO2013063186A2 (enExample)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
JP2016531849A (ja) * 2013-09-20 2016-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
CN108699152A (zh) * 2016-02-18 2018-10-23 伊兰科美国公司 嵌合犬抗cd20抗体
US10106607B2 (en) 2013-12-20 2018-10-23 Intervet Inc. Caninized antibodies
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体
US11505585B2 (en) 2013-12-24 2022-11-22 argenx BV FcRn antagonists and methods of use
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
WO2023012486A1 (en) * 2021-08-06 2023-02-09 Petmedix Ltd Antibody fc variants
US11591388B2 (en) 2019-06-07 2023-02-28 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
US12221486B2 (en) 2015-12-18 2025-02-11 Intervet Inc. Caninized human antibodies to human IL-4R alpha
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
US12344678B2 (en) 2022-06-15 2025-07-01 argenx BV FcRn/HSA binding molecules and methods of use
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010008A2 (pt) * 2011-10-26 2018-09-04 Novartis Ag anticorpos monoclonais, seus usos e ácidos nucleicos
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
WO2021165417A1 (en) 2020-02-19 2021-08-26 Adivo Gmbh Modified fc regions
MX2022013840A (es) * 2020-05-04 2023-02-09 Inhibrx Inc Polipéptidos de unión a pd-1 canina y usos de los mismos.
US20220024904A1 (en) * 2020-07-06 2022-01-27 Research Foundation Of The City University Of New York Reagent for bioconjugation via irreversible rebridging of disulfide linkages
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
JPWO2024158001A1 (enExample) 2023-01-25 2024-08-02
WO2025121944A1 (ko) * 2023-12-08 2025-06-12 주식회사 박셀바이오 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5977322A (en) * 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69939939D1 (de) 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
KR20020020730A (ko) 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8165535B2 (en) 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2003089930A1 (en) * 2002-04-22 2003-10-30 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
JPWO2005075640A1 (ja) 2004-02-10 2008-01-10 学校法人日本大学 イヌｃｄ２０遺伝子
EP1751187A2 (en) 2004-05-28 2007-02-14 Idexx Laboratories, Inc. Canine cd20 compositions
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
KR101378302B1 (ko) 2006-12-20 2014-03-28 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2227546B1 (en) 2007-12-21 2016-05-04 Novartis AG Mammalian expression vector
RU2528858C2 (ru) 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона
EP2725037A1 (en) 2008-09-04 2014-04-30 Vet Therapeutics, Inc. Monoclonal antibodies binding canine CD20
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
JP2012521784A (ja) * 2009-03-30 2012-09-20 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー イヌＦｃ部分を含む融合タンパク質
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
WO2011109662A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109108A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
BR112014010008A2 (pt) * 2011-10-26 2018-09-04 Novartis Ag anticorpos monoclonais, seus usos e ácidos nucleicos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2771694A4 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531849A (ja) * 2013-09-20 2016-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
JP2020011984A (ja) * 2013-09-20 2020-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
JP7480248B2 (ja) 2013-09-20 2024-05-09 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
JP2023002678A (ja) * 2013-09-20 2023-01-10 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
US11274152B2 (en) 2013-09-20 2022-03-15 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US11248047B2 (en) 2013-12-20 2022-02-15 Intervet Inc. Caninized antibodies
US12252536B2 (en) 2013-12-20 2025-03-18 Intervet Inc. Caninized antibodies
US10106607B2 (en) 2013-12-20 2018-10-23 Intervet Inc. Caninized antibodies
US10711061B2 (en) 2013-12-20 2020-07-14 Intervet Inc. Antibodies against canine PD-1
US11680097B2 (en) 2013-12-20 2023-06-20 Intervet Inc. Antibodies against canine PD-1
US11505585B2 (en) 2013-12-24 2022-11-22 argenx BV FcRn antagonists and methods of use
US11447561B2 (en) 2014-09-30 2022-09-20 Intervet, Inc. PD-L1 antibodies binding canine PD-L1
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
WO2016142782A1 (en) * 2015-03-09 2016-09-15 Argen-X N.V. Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
AU2016230827B2 (en) * 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
EP4006051A1 (en) * 2015-03-09 2022-06-01 Argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonists
EA038178B1 (ru) * 2015-03-09 2021-07-20 Ардженкс Бвба СПОСОБЫ УМЕНЬШЕНИЯ УРОВНЯ Fc-СОДЕРЖАЩИХ АГЕНТОВ В СЫВОРОТКЕ С ПРИМЕНЕНИЕМ FcRn-АНТАГОНИСТОВ
US12221486B2 (en) 2015-12-18 2025-02-11 Intervet Inc. Caninized human antibodies to human IL-4R alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CN108699152A (zh) * 2016-02-18 2018-10-23 伊兰科美国公司 嵌合犬抗cd20抗体
CN108699152B (zh) * 2016-02-18 2022-08-19 伊兰科美国公司 嵌合犬抗cd20抗体
US12195548B2 (en) 2016-02-18 2025-01-14 Elanco Us Inc. Chimeric canine anti-CD20 antibody
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US12049503B2 (en) 2017-05-30 2024-07-30 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
EP3866842A4 (en) * 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体
US11591388B2 (en) 2019-06-07 2023-02-28 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
WO2023012486A1 (en) * 2021-08-06 2023-02-09 Petmedix Ltd Antibody fc variants
US12344678B2 (en) 2022-06-15 2025-07-01 argenx BV FcRn/HSA binding molecules and methods of use

Also Published As

Publication number Publication date
WO2013063186A3 (en) 2014-07-31
EP2771694A4 (en) 2015-08-05
JP6316195B2 (ja) 2018-04-25
CA2853637C (en) 2023-04-04
EP4530630A3 (en) 2025-06-18
US20150125453A1 (en) 2015-05-07
RU2623122C2 (ru) 2017-06-22
EP2771694A2 (en) 2014-09-03
AU2012328819B2 (en) 2017-08-03
EP3378489A1 (en) 2018-09-26
RU2014120804A (ru) 2015-12-10
JP2014532649A (ja) 2014-12-08
US11319377B2 (en) 2022-05-03
BR112014010008A2 (pt) 2018-09-04
AU2012328819A1 (en) 2014-04-17
CA2853637A1 (en) 2013-05-02
EP4530630A2 (en) 2025-04-02
US20170355775A1 (en) 2017-12-14
US20220251230A1 (en) 2022-08-11
US9790280B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
US20220251230A1 (en) Monoclonal antibodies and methods of use
US11168144B2 (en) Activatable anti-PDL1 antibodies, and methods of use thereof
CN109152798B (zh) 特异于糖基化的pd-1的抗体及其使用方法
CN105037543B (zh) 治疗性dll4结合蛋白
CA2994214C (en) Humanized anti-ccr7 receptor antibodies
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
TW202328191A (zh) 使用her3抗原結合分子的癌症之治療及預防
US20240043512A1 (en) Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
CN114761042A (zh) Il-38特异性抗体
US20240174741A1 (en) Il-38-specific antibodies
CN118632871A (zh) 抗vista抗体及其用途
CN117677396A (zh) Il-38特异性抗体
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
TW201400501A (zh) 新穎抗體及其用途
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1
HK40058922A (en) Antibodies targeting epn1
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12842976

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012328819

Country of ref document: AU

Date of ref document: 20121025

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014538974

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2853637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14354280

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012842976

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014120804

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014010008

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014010008

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140425